Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
Anne-Genevieve MarcelinCharlotte CharpentierPantxika BellecaveBasma AbdiMarie-Laure ChaixVirginie FerreStéphanie RaymondDjeneba FofanaLaurence BocketAudrey MirandHelene Le Guillou-GuillemetteBrigitte MontesCorinne AmielCoralie PallierSamira Fafi-KremerAnne De MonteElodie Alessandri-GradtCaroline ScholtesAnne MaillardHelene JeulinMagali Bouvier-AliasCatherine RousselGeorges Dos SantosAnne Signori-SchmuckJulia DinaSophie ValletKarl SteficCathia SouliéVincent CalvezDiane DescampsPhilippe Flandrenull nullPublished in: The Journal of antimicrobial chemotherapy (2021)
This study is one of the largest studies characterizing integrase resistance in patients failing any INSTI-containing 2DR or 3DR in routine clinical care and reveals factors associated with emergence of integrase resistance that should be taken into consideration in clinical management. No difference was evidenced between patients receiving a 2DR or a 3DR.